Physician

Perrie L Ryan, M.D.

According to 2025 Medicare claims, Perrie Ryan, M.D. (NPI: 1073530432) practices hematology/oncology in the Columbia, SC market, with the plurality of this provider's patient population coming from Lexington, SC. This provider's primary affiliated billing organization is LEXINGTON HEALTH INC (NPI: 1932706264; TIN: 85-2276567) and primary practice location at 29169-4848. Ryan is affiliated with the AnewCare Collaborative, LLC (ACO ID: A1241), participating under the MSSP model.

Ryan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,183 traditional Medicare patients, billed 266,971 HCPCS/CPT codes, and received $4,765,846 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 1,623 prescription claims across 245 beneficiaries totaling $3,913,712 in drug costs, led by Xtandi (Enzalutamide). DME data shows 101 claims. Open Payments data shows 71 records totaling $1,577. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $125,227 to $4,765,846. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,711,775 to $3,913,712. In contrast, DME billing represents a smaller volume and declined steadily, from $4,809 to $681.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	312	1,470	$125,227
2016	274	9,245	$112,672
2017	362	97,832	$868,703
2018	611	143,735	$1,679,524
2019	839	190,111	$2,652,525
2020	941	198,195	$3,039,864
2021	1,086	189,429	$3,069,999
2022	1,172	209,880	$3,496,471
2023	1,197	253,984	$4,212,644
2024	1,183	266,971	$4,765,846

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	100	698	$1,711,775
2016	72	364	$851,373
2017	72	410	$222,399
2018	103	623	$200,343
2019	156	975	$705,345
2020	170	1,222	$1,001,536
2021	192	1,243	$1,878,424
2022	221	1,242	$3,037,184
2023	230	1,372	$3,082,747
2024	245	1,623	$3,913,712

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	63	$4,809
2016	N/R	23	$1,048
2017	N/R	51	$975
2018	N/R	178	$10,027
2019	N/R	68	$6,217
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	106	$59,543
2024	N/R	101	$2,482

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	315	641	$10
36415	Insertion of needle into vein for collection of blood sample	546	1,532	$8
80048	Blood test, basic group of blood chemicals (calcium, total)	288	743	$8
80076	Liver function blood test panel	276	664	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	595	1,614	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	74	2,220	$900,626
Revlimid	Lenalidomide	33	882	$539,088
Abiraterone Acetate	Abiraterone Acetate	137	4,230	$400,713
Inlyta	Axitinib	22	660	$342,691
Lenalidomide	Lenalidomide	29	784	$323,243

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	24	$950
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	29	$426
J8520	Capecitabine, oral, 150 mg	N	N/R	19	$409
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	11	$357
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	71	$1,577	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Perrie L. Ryan, M.D.?

Tedicare shows public-source Medicare data for Perrie L. Ryan, M.D. (NPI 1073530432), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Perrie L. Ryan, M.D. have ACO affiliation data?

Perrie L. Ryan, M.D. is shown with ACO affiliation data for AnewCare Collaborative, LLC (MSSP, ACO ID A1241).

What billing organization is linked to Perrie L. Ryan, M.D.?

Perrie L. Ryan, M.D. is linked to LEXINGTON HEALTH INC (billing NPI 1932706264) in the available physician profile data.

Does Perrie L. Ryan, M.D. have Open Payments data?

Perrie L. Ryan, M.D. has 71 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.